| Eiger BioPharmaceuticals, Inc. |
73079005030 |
Zokinvy Oral Capsule 50 MG 30 pack |
2021-01-25 |
21510.0000 |
ZOKINVY is the first and only FDA approved treatment for Progeria (Hutchinson-Gilford Progeria Syndrome, or HGPS) and Processing Deficient Progeroid Laminopathies, very rare genetic diseases causing children to age rapidly resulting in a median survival rate of 14.5 years for patients that are not treated with ZOKINVY. As a general matter, Eiger's activities supporting the launch are designed to educate providers about the approved indication, efficacy and safety data contained within the FDA approved label.
If requested, educational materials will be provided to patients and families to support drug access and affordability for ZOKINVY to ensure rapid access to this critical therapy. Eiger is committed in ensuring availability of its products to those patients in need. Eiger considered its price determination with comparisons to similar ultra-orphan agents with significant clinical benefit and disease modification as well as development costs, complexity of manufacturing, distribution, access, education, and storage. |
None |
15 |
1 |
1 |
None |
None |
None |
None |
None |
None |
| Eiger BioPharmaceuticals, Inc. |
73079007530 |
Zokinvy Oral Capsule 75 MG 30 pack |
2021-01-25 |
32265.0000 |
ZOKINVY is the first and only FDA approved treatment for Progeria (Hutchinson-Gilford Progeria Syndrome, or HGPS) and Processing Deficient Progeroid Laminopathies, very rare genetic diseases causing children to age rapidly resulting in a median survival rate of 14.5 years for patients that are not treated with ZOKINVY. As a general matter, Eiger's activities supporting the launch are designed to educate providers about the approved indication, efficacy and safety data contained within the FDA approved label.
If requested, educational materials will be provided to patients and families to support drug access and affordability for ZOKINVY to ensure rapid access to this critical therapy. Eiger is committed in ensuring availability of its products to those patients in need. Eiger considered its price determination with comparisons to similar ultra-orphan agents with significant clinical benefit and disease modification as well as development costs, complexity of manufacturing, distribution, access, education, and storage. |
None |
15 |
1 |
1 |
None |
None |
None |
None |
None |
None |
| Eli Lilly and Company |
00002121001 |
TAUVID™ injection for intravenous use 10 mCi 1 syringe |
2021-01-11 |
3500.0000 |
None |
1 |
910000 |
None |
1 |
None |
None |
None |
None |
TAUVID™, a radioactive diagnostic agent, was approved by the FDA in May 2020 for positron emission tomography (PET) imaging of the brain to estimate the density and distribution of aggregated tau neurofibrillary tangles (NFTs) in adult patients with cognitive impairment who are being evaluated for Alzheimer's disease (AD).
Based on Alzheimer's Disease Facts and Figures, [https://www.alz.org/media/Documents/alzheimers-facts-and-figures.pdf], the incidence of Alzheimer's in the United States is 910,000 per year (an average of 75,833/month). Patients with Alzheimer's may or may not be prescribed TAUVID for use in diagnostic imaging.
In 2013, Lilly announced that it had acquired two investigational positron emission tomography (PET) tracers from Siemens Molecular Imaging, Inc. One of the acquired tracers was flortaucipir F 18. Pursuant to California SB 17, Lilly is limiting its response to what is in the public domain or otherwise publicly available. Lilly does not believe the acquisition date or cost is in the public domain. [https://investor.lilly.com/news-releases/news-release-details/lilly-acquires-novel-tau-tangle-diagnostic-program-bolster]
All information is provided by Eli Lilly and Company ("Lilly") to the best of our knowledge at the time of submission. Lilly provides this report consistent with its understanding and interpretation of California Health and Safety Code Chapter 9 §127675-127686 and its related provisions. In providing this report, Lilly does not waive any rights that it may have at law or in equity with respect to the applicability, interpretation, or application of California Health and Safety Code Chapter 9 §127675-127686 as it may relate to Lilly or any of its affiliates now or in the future. Lilly, on behalf of itself and affiliates, expressly reserves all such rights. Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Lilly believes is otherwise in the public domain or publicly available. |
https://reports.siera.oshpd.ca.gov/api/report/drug-pricing/attachment?id=464 |
| Epic Pharma |
42806056201 |
Chlordiazepoxide Hcl Cap 10mg 100ct |
2021-06-17 |
1686.0000 |
None |
1 |
1940 |
None |
None |
None |
None |
None |
None |
None |
None |
| Epic Pharma |
42806056301 |
Chlordiazepoxide Hcl Cap 25mg 100ct |
2021-06-17 |
1786.0000 |
None |
1 |
2825 |
None |
None |
None |
None |
None |
None |
None |
None |
| Estreno Pharma |
72763020110 |
Tavaborole Topical Solution, 5% |
2021-02-11 |
1284.2000 |
Generic launch- priced with competitive market. |
None |
45000000 |
None |
None |
None |
None |
None |
None |
ANDA approved 2/3/2021
ANDA approval was in the name of Flatwing Pharmaceuticals, the ANDA was just transferred to IdentiRx of which Estreno Pharmaceuticals is the distributor for IdentiRx. Estreno controls the WAC. |
None |
| Eton Pharmaceuticals, Inc. |
71863011460 |
Carglumic acid tablet for oral suspension 200mg |
2021-12-20 |
10921.8000 |
"To market CARGLUMIC ACID, Eton designed activities to increase awareness and understanding with healthcare providers about CARGLUMIC ACID. Marketing activities will include education and training provided by our sales force and by contracted speakers to health care providers. Consumer-directed communications to educate patients on the disease state and CARGLUMIC ACID are planned. At Eton, we are driven by rigorous science and committed to ensuring patients have access to our innovative medicines. We responsibly price our drugs by balancing the value of the outcomes and innovation they bring to patients and the health care system within market and societal expectations.
The product is launching at a price 18% lower than the branded product to provide broader access to the drug at a lower cost for patients. Eton's pricing plan is set for CARGLUMIC ACID prices at approximately cost plus a margin to cover Eton's overhead and research and development expenses. " |
None |
10 |
None |
None |
2021-10-28 |
3250000.0000 |
None |
None |
None |
None |
| Exelan Pharmaceuticals, Inc. |
76282067830 |
Efavirenz-Emtricitab-Tenofovir Oral Tablet 600-200-300 MG |
2021-04-27 |
1599.9000 |
None |
1 |
1200000 |
None |
None |
None |
None |
None |
None |
Product not acquired |
None |
| Exelan Pharmaceuticals, Inc. |
76282067730 |
EMTRICITABINE AND TENOFOVIR DF TAB 200mg/300mg |
2021-05-07 |
852.5300 |
None |
1 |
1200000 |
None |
None |
None |
None |
None |
None |
Product not acquired |
None |